<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408562</url>
  </required_header>
  <id_info>
    <org_study_id>sNN0031-004</org_study_id>
    <nct_id>NCT02408562</nct_id>
  </id_info>
  <brief_title>Study on Tolerability of Repeat i.c.v. Administration of sNN0031 Infusion Solution in Patients With PD</brief_title>
  <official_title>A Phase 1, Multicentre, Randomised, Double-blind Study to Assess Safety and Tolerability of Repeated Intracerebroventricular Administration of sNN0031 Infusion Solution to Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newron Sweden AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Newron Sweden AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, randomised, placebo-controlled study to assess the safety and tolerability&#xD;
      of two 2-weeks cycles of i.c.v. administration of sNN0031 infusion solution to patients with&#xD;
      PD of moderate severity with persisting on-off symptoms in spite of other PD medications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Issues with development and supply of infusion system for delivery of IMP. Prolonged approval&#xD;
    process for the clinical study sNN0031-004.&#xD;
  </why_stopped>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of sNN0031 [Number of Adverse Events (AE) and Serious Adverse Events (SAE) occurring in each group over the study duration]</measure>
    <time_frame>10 months</time_frame>
    <description>Number of AEs and SAEs occurring in each group over the study duration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak concentrations of sNN0031 in cerebrospinal fluid during two 14 day continuous infusion cycles</measure>
    <time_frame>14 days x 2</time_frame>
    <description>To explore peak concentrations of Platelet Derived Growth Factor-BB (PDGF-BB) levels in cerebrospinal fluid (CSF) during two different treatment cycles of 70 μg sNN0031 each separated by 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pump flow error rate</measure>
    <time_frame>10 months</time_frame>
    <description>Performance of the Medtronic SynchroMed® II Infusion System - Pump flow error rate within 25%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with AEs related to the Implanted Infusion System</measure>
    <time_frame>10 months</time_frame>
    <description>Number of AEs and SAEs related to the Medtronic SynchroMed® II Infusion System occurring in each group over the study duration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Explorative evaluation of changes to the Modified Hoehn &amp;Yahr stage following two cycles of sNN0031</measure>
    <time_frame>10 monhts</time_frame>
    <description>To explore the change from baseline in relevant efficacy related variables:&#xD;
o Modified Hoehn &amp;Yahr stage</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative evaluation of changes to the Unified Parkinson's disease rating scale (UPDRS) following two cycles of sNN0031</measure>
    <time_frame>10 monhts</time_frame>
    <description>To explore the change from baseline in relevant efficacy related variables:&#xD;
o Unified Parkinson's disease rating scale (UPDRS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative evaluation of changes to the Parkinson's disease questionnaire (PDQ-39) following two cycles of sNN0031</measure>
    <time_frame>10 monhts</time_frame>
    <description>To explore the change from baseline in relevant efficacy related variables:&#xD;
o Parkinson's disease questionnaire (PDQ-39)</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative evaluation of changes to the Dyskinesia rating scale (DRS) following two cycles of sNN0031</measure>
    <time_frame>10 monhts</time_frame>
    <description>To explore the change from baseline in relevant efficacy related variables:&#xD;
o Dyskinesia rating scale (DRS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative evaluation of changes to the o Non-motor symptom scale (NMSS 30) following two cycles of sNN0031</measure>
    <time_frame>10 monhts</time_frame>
    <description>To explore the change from baseline in relevant efficacy related variables:&#xD;
o Non-motor symptom scale (NMSS 30)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in presynaptic dopamine transporter (DAT) binding</measure>
    <time_frame>10 months</time_frame>
    <description>To explore changes in presynaptic dopamine transporter (DAT) binding in basal ganglia by using DaTscan</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative evaluation of potentially relevant biomarkers (inflammatory mediators) in plasma and CSF during and after two cycles of sNN0031</measure>
    <time_frame>10 months</time_frame>
    <description>To explore potentially relevant biomarkers in plasma and CSF - inflammatory mediators.</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative evaluation of potentially relevant biomarkers (urate) in plasma and CSF during and after two cycles of sNN0031</measure>
    <time_frame>10 months</time_frame>
    <description>To explore potentially relevant biomarkers in plasma and CSF - urate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative evaluation of potentially relevant biomarkers (DJ-1/Park7) in plasma and CSF during and after two cycles of sNN0031</measure>
    <time_frame>10 months</time_frame>
    <description>To explore potentially relevant biomarkers in plasma and CSF - DJ-1/Park7.</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative evaluation of potentially relevant biomarkers (alpha-synuclein) in plasma and CSF during and after two cycles of sNN0031</measure>
    <time_frame>10 months</time_frame>
    <description>To explore potentially relevant biomarkers in plasma and CSF - alpha-synuclein.</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative evaluation of potentially relevant biomarkers (haemoglobin) in plasma and CSF during and after two cycles of sNN0031</measure>
    <time_frame>10 months</time_frame>
    <description>To explore potentially relevant biomarkers in plasma and CSF - haemoglobin.</description>
  </other_outcome>
  <other_outcome>
    <measure>Explorative evaluation of potentially relevant biomarkers (nitrite/nitrate) in plasma and CSF during and after two cycles of sNN0031</measure>
    <time_frame>10 months</time_frame>
    <description>To explore potentially relevant biomarkers in plasma and CSF - nitrite/nitrate.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>sNN0031</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sNN0031 Infusion Solution (in aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Articifial Cerebro Spinal Fluid (aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>i.c.v. infusion of sNN0031 by an Implanted infusion system</intervention_name>
    <description>I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.</description>
    <arm_group_label>sNN0031</arm_group_label>
    <other_name>rhPDGF-BB</other_name>
    <other_name>Medtronic SynchroMed® II Infusion System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>i.c.v. infusion of aCSF by an Implanted infusion system</intervention_name>
    <description>I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo, Artificial Cerebrospinal fluid</other_name>
    <other_name>Medtronic SynchroMed® II Infusion System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Disease duration ≥ 5 years (diagnosis based on medical history and neurological&#xD;
             examination).&#xD;
&#xD;
          2. Male or female, age 30 - 75 years inclusive.&#xD;
&#xD;
          3. Motor fluctuations, with OFF-time &gt;1.5 hours during the day&#xD;
&#xD;
          4. A Hoehn and Yahr stage of 2 to 4 during OFF phase&#xD;
&#xD;
          5. Score &gt;22 on the UPDRS part III during ON phase&#xD;
&#xD;
          6. Patients should be L-dopa responsive and demonstrate at least a 30% decrease in the&#xD;
             UPDRS part III score after administration of L-dopa (L-dopa challenge test)&#xD;
&#xD;
          7. Optimised and stable anti-Parkinson treatment for at least 3 months before screening&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. The patient has any indication of forms of parkinsonism other than idiopathic&#xD;
             Parkinson's disease&#xD;
&#xD;
          2. The patient is in a late stage of Parkinson's disease, and is experiencing severe,&#xD;
             disabling peak-dose or biphasic dyskinesia and/or unpredictable or widely swinging&#xD;
             fluctuations in their symptoms&#xD;
&#xD;
          3. Patients who are on treatment with Duodopa or Apomorphine pump at the time of&#xD;
             screening&#xD;
&#xD;
          4. The patient has an implanted shunt for the drainage of CSF or an implanted Central&#xD;
             Nervous System (CNS) catheter, or have received neurosurgical intervention related to&#xD;
             PD (e.g. deep brain stimulation, thalamotomy etc.) or is scheduled to do so during the&#xD;
             trial period&#xD;
&#xD;
          5. Concurrent diagnoses of dementia with a score of 24 or lower on Mini-Mental State&#xD;
             Examination (MMSE).&#xD;
&#xD;
          6. The patient is depressed, as indicated by a Hamilton Depression Rating Scale&#xD;
             (GRID-HAMD, 17-item scale) score &gt; 17&#xD;
&#xD;
          7. Patients who are at high risk of suicide as judged by the rating of the Columbia&#xD;
             Symptoms Suicide Rating Scale (C-SSRS)&#xD;
&#xD;
          8. Patients with a history of increased intracranial pressure&#xD;
&#xD;
          9. Ophthalmologic examination (funduscopy and visual acuity by Early Treatment of&#xD;
             Diabetic Retinopathy Study (EDTRS) and perimetry) with clinically significant findings&#xD;
             that imply safety concerns for this study&#xD;
&#xD;
         10. The patient has a current clinically significant gastrointestinal, renal, hepatic,&#xD;
             endocrine, pulmonary or cardiovascular disease&#xD;
&#xD;
         11. The patient has heart problems or a significant ECG abnormality&#xD;
&#xD;
         12. Uncontrolled hypertension.&#xD;
&#xD;
         13. The patient has in the past experienced psychotic symptoms (e.g. schizophrenia or&#xD;
             psychotic depression)&#xD;
&#xD;
         14. The patient has a mental or physical condition which would preclude performing study&#xD;
             assessments&#xD;
&#xD;
         15. Alcohol or substance dependence within the prior 12 months, or abuse within 3 months,&#xD;
             with the exceptions of nicotine&#xD;
&#xD;
         16. MRI examination with findings of tumours or potential sources of pathological&#xD;
             bleedings, or any abnormality that may put the patient at risk&#xD;
&#xD;
         17. History of structural brain disease including tumours and hyperplasia&#xD;
&#xD;
         18. Ongoing or suspected primary or recurrent malignant disease (currently active or in&#xD;
             remission for less than one year)&#xD;
&#xD;
         19. Any disorder that precludes a surgical procedure, alters wound healing or renders&#xD;
             chronic i.c.v. delivery or device implants medically unsuitable&#xD;
&#xD;
         20. The patient has a history or a current diagnosis of HIV, Hepatitis B or C.&#xD;
&#xD;
         21. Increased susceptibility to infections&#xD;
&#xD;
         22. Women who are pregnant or breast feeding or unwilling to use adequate contraception&#xD;
             during the trial (only women of child bearing potential)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Håkan Widner, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum-Bremerhaven</name>
      <address>
        <city>Bremerhaven</city>
        <zip>DE-27574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Becaplermin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

